2-amino-6-(benzylamino)-9-(β-D-ribofuranosyl)purine | 26783-32-4

• 分子结构分类: 有机化合物 - 核苷、核苷酸和类似物 - 嘌呤核苷
• 英文名称: 2-amino-6-(benzylamino)-9-(β-D-ribofuranosyl)purine
• 英文别名: 2-amino-N⁶-benzyladenosine；2-Amino-N-benzyladenosine；(2R,3R,4S,5R)-2-[2-amino-6-(benzylamino)purin-9-yl]-5-(hydroxymethyl)oxolane-3,4-diol
• CAS: 26783-32-4
• 化学式: C₁₇H₂₀N₆O₄
• 分子量: 372.384
• InChiKey: VJNBCNYIASIYAV-XNIJJKJLSA-N

物化性质

• 熔点：
  120 °C(Solv: ethyl ether (60-29-7); methanol (67-56-1))
• 沸点：
  779.2±70.0 °C(Predicted)
• 密度：
  1.71±0.1 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  0.8
• 重原子数：
  27
• 可旋转键数：
  5
• 环数：
  4.0
• sp3杂化的碳原子比例：
  0.35
• 拓扑面积：
  152
• 氢给体数：
  5
• 氢受体数：
  9

反应信息

• 作为反应物：
  描述：

  2-amino-6-(benzylamino)-9-(β-D-ribofuranosyl)purine 在 disodium hydrogen arsenate heptahydrate 、 recombinant E_. coli purine nucleoside phosphorylase 作用下， 以 aq. buffer 为溶剂， 反应 16.0h， 以75%的产率得到2-amino-6-benzylaminopurine
  参考文献：
  名称：

  从核苷化学酶促合成细胞分裂素：核糖作为封闭基团†

  摘要：

  核苷磷酸化酶参与核苷生物合成的挽救途径，并催化核碱基与α - D-核糖-1-磷酸的可逆反应，生成相应的核苷和无机磷酸盐。这些反应的平衡向核苷转移，特别是在嘌呤的情况下。嘌呤核苷磷酸化酶（PNP，EC 2.4.2.1）在实验室和工业中广泛用于合成具有实际重要性的核苷。细菌PNP利用相对广泛的具有不同取代基的嘌呤形成相应的核苷，具有相对较宽的底物特异性。为了使反应朝相反的方向进行，我们使用了砷解作用而不是磷解作用。由于生成的α-的水解，该反应是不可逆的D-核糖-1-砷。结果，杂环碱以定量产率形成并且可以容易地分离。我们已经开发出一种新的细胞分裂素制备方法，该方法基于在PNP和Na 2 HAsO 4存在下酶解N 6取代的腺苷的N-糖苷键的方法。根据HPLC分析，转化以定量产率进行。在提出的策略中，核糖残基充当保护基。最终产品具有的ASO无污染4 3-已经检测到通过HPLC-HRMS; 已经提出了通过ESI-MS进行简单的砷分析检测。

  DOI：

  10.1039/c8ob00223a
• 作为产物：
  描述：

  2',3'-O-异丙亚基鸟苷 在 吡啶 、 4-二甲氨基吡啶 、 水 、 碘 、 1,8-二氮杂双环[5.4.0]十一碳-7-烯 、 三乙胺 、 N,N-二异丙基乙胺 、 三苯基膦 、 三氟乙酸 作用下， 以 甲苯 为溶剂， 反应 89.34h， 生成 2-amino-6-(benzylamino)-9-(β-D-ribofuranosyl)purine
  参考文献：
  名称：

  C6 上鸟苷和 2'-脱氧鸟苷的功能化：改进的 Appel 过程和咪唑的 SNAr 置换

  摘要：

  用咪唑/三苯基膦/碘/乙基二异丙胺处理糖保护的鸟苷和 2'-脱氧鸟苷的 2-N-三苯甲基衍生物，得到相应的 6-(咪唑-1-基)-2-(三苯甲基氨基)嘌呤核苷。用亲核试剂对咪唑部分进行 SNAr 置换，提供 2-氨基-6-取代的嘌呤核苷和 2'-脱氧核苷。†为了纪念和庆祝 Leroy B. Townsend 教授 70 岁生日。#这篇论文是：核酸相关化合物，122。论文 121 是参考文献。1.

  DOI：

  10.1081/ncn-120027823

文献信息

• Adenosine Analogues as Inhibitors of <i>Trypanosoma </i><i>b</i><i>rucei </i>Phosphoglycerate Kinase:  Elucidation of a Novel Binding Mode for a 2-Amino-N⁶-Substituted Adenosine
  作者：Jerome C. Bressi、Jungwoo Choe、Melinda T. Hough、Frederick S. Buckner、Wesley C. Van Voorhis、Christophe L. M. J. Verlinde、Wim G. J. Hol、Michael H. Gelb

  DOI：10.1021/jm000287a

  日期：2000.11.1

  As part of a project aimed at structure-based design of adenosine analogues as drugs against African trypanosomiasis, N-6-, 2-amino-N-6-, and N-2-substituted adenosine analogues were synthesized and tested to establish structure-activity relationships for inhibiting Trypanosoma brucei glycosomal phosphoglycerate kinase (PGK), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and glycerol-3-phosphate dehydrogenase (GPDH). Evaluation of X-ray structures of parasite PGK, GAPDH, and GPDH complexed with their adenosyl-bearing substrates led us to generate a series of adenosine analogues which would target all three enzymes simultaneously. There was a modest preference by PGK for NG-substituted analogues bearing the 2-amino group. The best compound in this series, 2-amino-N-6-[2 "-(p-hydroxyphenyl)ethyl]adenosine (46b), displayed a 23-fold improvement over adenosine with an IC50 of 130 muM. 2-[[2 "-(p-Hydroxyphenyl)ethyl]amino]adenosine (46c) was a weak inhibitor of T. brucei PGK with an IC50 of 500 muM. To explore the potential of an additive effect that having the N-6 and N-2 substitutions in one molecule might provide, the best ligands from the two series were incorporated into N-6,N-2-disubstituted adenosine analogues to yield N-6-(2 " -phenylethyl)-2-[(2 " -phenylethyl)amino]adenosine (69) as a 30 muM inhibitor of T. brucei PGK which is 100-fold more potent than the adenosine template. In contrast, these series gave no compounds that inhibited parasitic GAPDH or GPDH more than 10-20% when tested at 1.0 mM. A 3.0 Angstrom X-ray structure of a T, brucei PGK/46b complex revealed a binding mode in which the nucleoside analogue was flipped and the ribosyl moiety adopted a syn conformation as compared with the previously determined binding mode of ADP. Molecular docking experiments using QXP and SAS program suites reproduced this "flipped and rotated" binding mode.
• [EN] PHOSPHORAMIDATE DERIVATIVES OF GUANOSINE NUCLEOSIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS<br/>[FR] DÉRIVÉS DE PHOSPHORAMIDATE DE COMPOSÉS GUANOSINE NUCLÉOSIDE POUR LE TRAITEMENT D'INFECTIONS VIRALES
  申请人：UNIV CARDIFF

  公开号：WO2010081082A2

  公开（公告）日：2010-07-15

  Phosphoramidate compounds derived from guanine bases having enhanced therapeutic potency are provided, and these compounds in particular have enhanced potency with respect to treatment of viral infections, such as hepatitis C virus. Pharmaceutical compositions, methods of preparing the compounds, and methods of using the compounds and compositions to treat viral infections are also provided.